6533b835fe1ef96bd129f547
RESEARCH PRODUCT
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
Aangela VaccaroAntonio GiordanoMarina Elena CazzanigaAntonio RussoMaddalena BarbaEmilio BriaEmilio BriaCorrado FicorellaClaudio BottiNicla La VerdeClara NatoliValentina MagriLoretta D'onofrioCarlo GarufiRuggero De MariaMaria Rosaria ValerioGennaro CilibertoMario RoselliA. FabbriEmanuela MagnolfiGiuseppina Rosaria Rita RicciardiPatrizia ViciAlessandra CassanoEmanuela RisiIsabella SperdutiDaniele GeneraliDaniele MarinelliVito LorussoTeresa GamucciLorenzo LiviGiuseppe ToniniAntonino GrassadoniaEditta BaldiniMarco MazzottaLuca MoscettiSilverio TomaoClaudio ZamagniSilvia CarpanoOrnella GarroneIcro MeattiniGiuseppe SanguinetiEriseld KrasniqiLucia MentucciaKatia CannitaDaniele SantiniRossana MirabelliEnzo VeltriDomenico SergiAandrea MichelottiAlice VillaNicola TinariVincenzo AdamoA. BotticelliRamy KayalMirco PistelliDomenico CorsiPietro Del MedicoRossana BerardiEnrico CortesiGiacomo BarchiesiAlain GelibterIda ParisElisa LanducciPia Di StefanoLaura PizzutiPaolo MarchettiPaolo MarchettiLuisa CarbogninLuisa CarbogninFrancesco GiottaA.f. Scintosubject
0301 basic medicineOncologyPhysiologyReceptor ErbB-2Clinical BiochemistryAdo-Trastuzumab EmtansineSettore MED/06body mass index; HER2-positive metastatic breast cancer; pertuzumab; trastuzumab emtansinechemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalAged 80 and overeducation.field_of_studyUnivariate analysisMiddle AgedMetastatic breast cancerProgression-Free SurvivalQuartile030220 oncology & carcinogenesisHER2-positive metastatic breast cancerDisease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialtyPopulationBreast Neoplasmsbody mass indexAntibodies Monoclonal Humanized03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineHumansObesityeducationAgedtrastuzumab emtansinebusiness.industrynutritional and metabolic diseasesCell BiologyOverweightmedicine.disease030104 developmental biologychemistryTrastuzumab emtansineMED/06 - ONCOLOGIA MEDICAbusinessBody mass indexdescription
Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5-24.9, 25-29.9, and 30.0-34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p = .15), while BMI ≥ 30 was associated with worse OS (p = .003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p = .001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p = .03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-01-01 |